Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDA-1102 ointment versus placebo for rapidly proliferating actinic keratosis
2025-522482-30-00Phase 2Completed
- Sponsor
- Vidac Pharma
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in actinic keratosis (AK) comparing VDA-1102 ointment with Placebo ointment (2 arms). Primary endpoint: Modified PRO score of the marker lesion at 12 weeks. Started Feb 2026; status: completed.
02
Drugs
tuvatexib
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2025-522482-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522482-30-00.